RT Journal Article
SR Electronic
T1 Effectiveness of ChAdOx1 nCoV-19 Corona Virus Vaccine (Covishield™) in preventing SARS-CoV2 infection, Chennai, Tamil Nadu, India, 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.15.22273859
DO 10.1101/2022.04.15.22273859
A1 Murali, Sharan
A1 Sakthivel, Manikandanesan
A1 P, Kamaraj
A1 Venkataswamy, Vettrichelvan
A1 Thangaraj, Jeromie Wesley Vivian
A1 Shete, Anita
A1 John, Alby
A1 Arjun, Jaganathan
A1 C P, Girish Kumar
A1 Yadav, Pragya D
A1 Sahay, Rima
A1 Majumdar, Triparna
A1 Dhudhmal, Manisha
A1 Sivalingam, Azhagendran
A1 D, Sudha Rani
A1 D, Augustine
A1 R, Vijayaprabha
A1 M, Murali Mohan
A1 A, Suresh
A1 M, Punita
A1 G, Elavarasu
A1 C, Prabhakaran
A1 S, Dhana Priya Vadhani
A1 M, Prakash
A1 P, Ezhil
A1 Parasuraman, Ganeshkumar
A1 M, Jagadeesan
A1 Narnaware, Manish S
A1 Bedi, Gagandeep Singh
A1 Kaur, Prabhdeep
A1 Murhekar, Manoj V
YR 2022
UL http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273859.abstract
AB Background India experienced the second wave of the COVID-19 pandemic in March 2021, driven by the delta variant. Apprehensions around the usefulness of vaccines against delta variant posed a risk to the vaccination program. Therefore, we estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against COVID-19 infection among individuals ≥45 years in Chennai, India.Methods A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai, Tamil Nadu. The estimated sample size was 10,232. We enumerated individuals from all eligible households and periodically updated vaccination and COVID-19 infection data. We computed vaccine effectiveness with its 95% confidence interval for two doses of the Covishield vaccine against any COVID-19 infection.Results We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. The overall incidence of COVID-19 infection was 1099 per 100,000 population. The vaccine effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6 - 73.4) at least two weeks after receiving the second dose of Covishield. Genomic analysis of 74 (28 with two doses, 15 with one dose, and 31 with zero dose) out of the 90 aliquots collected from the 303 COVID-19 positive individuals in the 45+ age group showed delta variants and their sub-lineages.Conclusion We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute Human Ethics Committee of ICMR_- National Institute of Epidemiology gave ethical approval for this work Id - "NIE/IHEC/202105-01"I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors